

浏览全部资源
扫码关注微信
安徽中医药大学 第一附属医院,合肥 230031
Received:10 May 2021,
Published Online:29 November 2021,
Published:05 February 2022
移动端阅览
吕勇,鲍容,张磊等.加味参苓白术散对持续性不卧床腹膜透析患者胃肠功能障碍及蛋白质-能量消耗的干预作用[J].中国实验方剂学杂志,2022,28(03):116-122.
LYU Yong,BAO Rong,ZHANG Lei,et al.Effect of Modified Shenling Baizhusan on Gastrointestinal Dysfunction and Protein-energy Wasting in Continuous Ambulatory Peritoneal Dialysis Patients[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(03):116-122.
吕勇,鲍容,张磊等.加味参苓白术散对持续性不卧床腹膜透析患者胃肠功能障碍及蛋白质-能量消耗的干预作用[J].中国实验方剂学杂志,2022,28(03):116-122. DOI: 10.13422/j.cnki.syfjx.20220393.
LYU Yong,BAO Rong,ZHANG Lei,et al.Effect of Modified Shenling Baizhusan on Gastrointestinal Dysfunction and Protein-energy Wasting in Continuous Ambulatory Peritoneal Dialysis Patients[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(03):116-122. DOI: 10.13422/j.cnki.syfjx.20220393.
目的
2
观察和分析加味参苓白术散对持续性不卧床腹膜透析(CAPD)脾虚挟瘀浊证患者胃肠功能障碍及蛋白质-能量消耗(PEW)的干预作用。
方法
2
CAPD脾虚挟瘀浊证患者66例,随机分为观察组和对照组各33例,每组3例患者退出观察,实际完成60例。两组均予CAPD和常规对症治疗,观察组服用加味参苓白术散颗粒(1剂/d,分早晚2次服),对照组口服双歧杆菌二联活菌胶囊(1.05 g/次,每日2次),疗程12周。观察两组患者治疗前后中医证候积分值、胃肠道症状分级量表(GSRS)评分、营养不良-微炎症(MIS)评分的变化;检测患者血清白蛋白(ALB),前白蛋白(PA),转铁蛋白(TRF),胃泌素-17(G-17),血清肿瘤坏死因子-
α
(TNF-
α
),
γ
干扰素(IFN-
γ
)和白细胞介素-10(IL-10)水平,计算体质指数(BMI)的变化情况。
结果
2
治疗后观察组中医证候疗效优于对照组(
Z
=-2.591,
P
<
0.05),中医证候积分明显下降(
P
<
0.05)。与本组治疗前及对照组治疗后比较,观察组各主要症状积分,MIS评分和G-17均明显下降(
P
<
0.05)。与本组治疗前比较,两组GSRS评分值明显下降(
P
<
0.05),观察组比对照组降低幅度大(
P
<
0.05)。与本组治疗前及对照组治疗后比较,观察组ALB,PA,TRF和BMI均明显升高(
P
<
0.05)。与本组治疗前比较,两组患者血清TNF-
α
,IFN-
γ
均明显下降(
P
<
0.05)。与本组治疗前及对照组治疗后比较,观察组IL-10水平明显升高(
P
<
0.05)。
结论
2
加味参苓白术散可改善CAPD脾虚挟瘀浊证患者胃肠功能障碍和PEW。
Objective
2
To observe and analyze the effect of modified Shenling Baizhusan on gastrointestinal dysfunction and protein-energy wasting (PEW) of continuous ambulatory peritoneal dialysis (CAPD) patients with the syndrome of spleen deficiency, blood stasis, and dampness.
Method
2
A total of 66 CAPD patients with the above syndrome were randomized into the observation group and control group, 33 cases in each group. However, 3 cases in each group dropped out, finally leaving 30 cases in each group. Both groups received CAPD and conventional symptomatic treatment. On this basis, the observation group was given modified Shenling Baizhusan (1 bag/day, once in the morning and again in the evening, 12 weeks), and the control group the bifidobacterium capsules (1.05 g/time, twice/day, 12 weeks). Before and after treatment, the traditional Chinese medicine (TCM) syndrome score, gastrointestinal symptom rating scale (GSRS) score, and malnutrition-inflammation score (MIS) in two groups were recorded, and the levels of serum albumin (ALB), prealbumin (PA), transferrin (TRF), gastrin-17 (G-17), tumor necrosis factor alpha (TNF-
α
), interferon-
γ
(IFN-
γ
), and interleukin-10 (IL-10) were detected. Moreover, body mass index (BMI) was calculated.
Result
2
After treatment, the alleviation of the TCM syndrome in the observation group was better than that in the control group (
Z
=-2.591,
P
<
0.05), and the TCM syndrome score in the observation group was lower than that in the control (
P
<
0.05). The symptom scores, MIS, and G-17 of the observation group were significantly decreased compared with those before observation and in the control group (
P
<
0.05). After treatment, the GSRS scores of the two groups were significantly lower than those before treatment (
P
<
0.05), particularly the observation group (
P
<
0.05). ALB, PA, TRF, and BMI of the observation group after treatment were increased compared with those before treatment and those of the control group after treatment (
P
<
0.05). After treatment, serum TNF-
α
and IFN-
γ
of the two groups were significantly reduced compared with those before treatment (
P
<
0.05), and the levels of the two in the observation group were significantly lower in the observation group than in the control group (
P
<
0.05). After treatment, IL-10 level of the observation group was higher than that before treatment and in the control group (
P
<
0.05).
Conclusion
2
The modified Shenling Baizhusan can relieve the gastrointestinal dysfunction and PEW in CAPD patients with the syndrome of spleen deficiency, blood stasis, and dampness.
黄美英 , 王洁 , 黄鹏 , 等 . 血液透析和腹膜透析对终末期肾病患者预后的影响及其安全性比较 [J]. 现代生物医学进展 , 2018 , 18 ( 9 ): 1746 - 1749 .
陈香美 , 全国透析数据登记报告 [R]. 北京 : 中国医师协会 , 2019 .
王琳娜 , 刘志启 , 赵军 , 等 . 持续性非卧床腹膜透析患者死亡原因分析 [J]. 齐齐哈尔医学院学报 , 2010 , 31 ( 24 ): 3894 - 3895 .
董睿 , 郭志勇 . 维持性透析患者的胃肠道症状 [J]. 肾脏病与透析肾移植杂志 , 2012 , 21 ( 5 ): 480 - 483,495 .
KRISHNAMOORTHY V , SUNDER S , MAHAPATRA H S , et al . Evaluation of protein-energy wasting and inflammation on patients undergoing continuous ambulatory peritoneal dialysis and its correlations [J]. Nephrourol Mon , 2015 , 7 ( 6 ): e33143 .
王文哲 , 毛辉辉 , 陈文莉 . 健脾益肾方加减治疗腹膜透析患者胃肠功能紊乱的疗效观察 [J]. 时珍国医国药 , 2017 , 28 ( 5 ): 1144 - 1145 .
钟锦 , 钟凌云 . 小柴胡汤合五苓散对维持性腹膜透析患者残余肾功能的保护及对腹膜纤维化、微炎症状态的影响 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 3 ): 114 - 119 .
赵奎 , 吕勇 . CAPD患者的中医症状调查及其预后影响因素的相关性分析 [D]. 合肥 : 安徽中医药大学 , 2018 .
吕勇 , 宋蓓蓓 , 金华 . 基于“治痿独取阳明”理论的中医综合疗法治疗腹膜透析并发不安腿综合征临床观察 [J]. 安徽中医药大学学报 , 2019 , 38 ( 5 ): 9 - 14 .
曹曼 , 吕勇 , 张磊 , 等 . 基于“脾主腹”理论观察加味参苓白术散对腹膜透析患者腹膜功能及纤维化指标的影响 [J]. 安徽中医药大学学报 , 2019 , 40 ( 3 ): 9 - 14 .
李姿慧 , 蔡荣林 , 孙娟 , 等 . 参苓白术散对脾虚湿困型溃疡性结肠炎大鼠结肠组织NF- κ B p65,I κ B α ,I κ K β 蛋白及mRNA表达的影响 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 19 ): 108 - 113 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 163 - 168 .
DROSSMAN D A . Functional gastrointestinal disorders:history,pathophysiology,clinical features and rome Ⅳ [J]. Gastroenterology , 2016 , 150 ( 11 ): 1262 - 1279 .
SVEDLUND J , SJÖDIN I , DOTEVALL G . GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease [J]. Dig Dis Sci , 1988 , 33 ( 2 ): 129 - 134 .
刘静 , 尹道馨 , 徐睿 , 等 . 改良主观全面营养评价法在慢性肾脏病患者中的应用 [J]. 临床和实验医学杂志 , 2012 , 11 ( 4 ): 243 - 246 .
肖月 , 石建伟 , 刘蕊 . MIS评分在诊断腹膜透析患者PEW中的应用 [J]. 同济大学学报:医学版 , 2017 , 38 ( 6 ): 92 - 96 .
倪兆慧 , 金海姣 . 中国腹膜透析发展70年 [J]. 中国血液净化 , 2019 , 18 ( 10 ): 661 - 663 .
陈香美 , 周建辉 . 中国腹膜透析技术发展现状与未来 [J]. 中国实用内科杂志 , 2013 , 33 ( 6 ): 413 - 415 .
LEINIG C E , MORAES T , RIBEIRO S , et al . Predictive value of malnutrition markers for mortality in peritoneal dialysis patients [J]. J Ren Nutr , 2011 , 21 : 176 - 183 .
王寒冰 , 姚源璋 . 微炎症状态下PD患者PEW的发生机制及药物干预 [J]. 中国中西医结合肾病杂志 , 2017 , 18 ( 12 ): 1126 - 1127 .
董睿 , 郭志勇 . 维持性腹膜透析患者胃肠道症状调查及相关因素分析 [J]. 第二军医大学学报 , 2013 , 34 ( 1 ): 29 - 36 .
魏萌 , 蒋红利 , 王志刚 , 等 . 尿毒症大鼠肠道菌群失调及其与微炎症状态的相关性 [J]. 西安交通大学学报:医学版 , 2013 , 34 ( 3 ): 341 - 345 .
雷洋洋 , 杨波 , 裴明 , 等 . 扶肾颗粒联合灌肠治疗腹膜透析患者胃肠功能障碍46例 [J]. 中国中西医结合外科杂志 , 2018 , 24 ( 4 ): 441 - 446 .
施珊珊 , 江振友 , 宋克玉 , 等 . 参苓白术散调节小鼠肠道菌群作用的实验研究 [J]. 广东医学 , 2011 , 32 ( 5 ): 562 - 564 .
黄雪霞 , 吴金玉 , 唐宇 , 等 . 参苓白术散对尿毒症小剂量腹膜透析临床疗效的影响 [J]. 中国中西医结合肾病杂志 , 2017 , 18 ( 4 ): 336 - 338 .
何伟明 , 高坤 , 周栋 , 等 . 丹参注射液对腹膜纤维化大鼠腹膜通透性的影响 [J]. 中国中西医结合肾病杂志 , 2009 , 10 ( 12 ): 1050 - 1053,1140 .
陈瑾 , 毛敏 , 张涛 , 等 . 腹膜透析和血液透析患者胃肠道症状的调查分析 [J]. 临床肾脏病杂志 , 2017 , 17 ( 6 ): 340 - 344 .
REN K , YONG C , YUAN H , et al . TNF- α inhibits SCF,ghrelin,and substance P expressions through the NF- κ B pathway activation in interstitial cells of Cajal [J]. Braz J Med Biol Res , 2018 , 51 ( 6 ): e7065 .
AL-SADI R , GUO S , YE D , et al . TNF-α modulation of intestinal tight junction permeability is mediated by NIK/IKK-α axis activation of the canonical NF- κ B pathway [J]. Am J Pathol , 2016 , 186 ( 5 ): 1151 - 1165 .
唐利群 , 周国平 . 慢性肾脏病患者干扰素 γ 的表达及其临床意义 [J]. 临床医学研究与实践 , 2016 , 9 ( 1 ): 1 - 2,6 .
郭军鹏 , 孟超 , 刘宏岩 . 补气中药对小鼠胃肠动力和激素水平的影响 [J]. 中国老年学杂志 , 2015 , 35 ( 11 ): 2920 - 2921 .
谢健航 , 林嘉 , 雷林生 , 等 . 茯苓总三萜抑制小鼠免疫反应及治疗大鼠佐剂性关节炎的实验研究 [J]. 中药药理与临床 , 2016 , 32 ( 6 ): 89 - 92 .
张仲林 , 钟玲 , 臧志和 , 等 . 参苓白术散对动物胃肠动力影响的实验研究 [J]. 时珍国医国药 , 2009 , 20 ( 12 ): 3151 - 3152 .
袁丕瑞 . 参苓白术散对免疫抑制小鼠免疫功能的影响研究 [J]. 临床合理用药 , 2011 , 4 ( 29 ): 67 - 68 .
0
Views
20
下载量
3
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621